Clinical Trial Update: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib [Phase 2]

View source ↗

Summary

Phase 2 clinical study of combination therapy ABSK043 and Firmonertinib is currently recruiting for non-small cell lung cancer with EGFR mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABSK043 (ABSK043)
• Firmonertinib (firmonertinib)

Snippet

Sponsor: Abbisko Therapeutics Co, Ltd | Conditions: Non-Small Cell Lung Cancer With EGFR Mutation | Phase 2 | Status: RECRUITING